Video: New vaccine to protect babies from whooping cough

by David Hover

Whooping cough, also known as pertussis, is a bacterial infection that can be fatal. Now, a new nasal vaccination aimed at infants aims to address an unmet medical need against this disease.

In Europe, (Pertussis) is in the increase, with more than 20.000 cases reported annually. Often infants fall victim to the disease, where it can be life-threatening. Possible complications include pneumonia, and collapsed lungs, leading to death in one in 200.

There is a vaccine on the market, but a newborn's immune system is too immature to respond to it. Therefore scientists at the Institute Pasteur in Lille, France have developed a new vaccine that the babies' immune system can deal with: it is administered intranasally to reproduce the natural conditions of infection as closely as possible. The new substance is currently undergoing clinical trials and has passed the first phase of testing on human adults successfully. The results were published on the last issue of the peer-reviewed journal Plos One.

This video is not supported by your browser at this time.

Read more: Camille Locht: An innovative solution to infant whooping cough

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments